Literature DB >> 25849618

Artificial miRNAs Targeting Mutant Huntingtin Show Preferential Silencing In Vitro and In Vivo.

Alex Mas Monteys1, Matthew J Wilson2, Ryan L Boudreau2, Ryan M Spengler2, Beverly L Davidson3.   

Abstract

Huntington's disease (HD) is a dominantly inherited neurodegenerative disease caused by CAG repeat expansion in exon 1 of huntingtin (HTT). Studies in mouse models of HD with a regulated mutant transgene show that continuous mutant allele expression is required for behavioral and pathological signs; when mutant HTT expression declined, neuronal degeneration improved. To date, it is unknown whether neural cells in the adult human brain can tolerate reduction in both normal and mutant alleles. Thus, it may be important to develop allele-specific silencing approaches. Several siRNA sequences targeting the CAG expanded motif or prevalent single-nucleotide polymorphisms (SNPs) in linkage disequilibrium with the mutant allele have been designed and their selectivity demonstrated in vitro. However, it is unknown whether these allele-specific siRNAs will retain their specificity when expressed from artificial RNAi platforms. Here, we designed CAG- and SNP- targeting artificial miRNAs and demonstrate that some, but not all, retained their selectivity in vitro using an allele-specific reporter system and in vivo in a transgenic mouse model developed to express normal and mutant human HTT alleles.

Entities:  

Year:  2015        PMID: 25849618     DOI: 10.1038/mtna.2015.7

Source DB:  PubMed          Journal:  Mol Ther Nucleic Acids        ISSN: 2162-2531            Impact factor:   10.183


  18 in total

Review 1.  Recent advances in molecular therapies for neurological disease: triplet repeat disorders.

Authors:  Pedro Gonzalez-Alegre
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

Review 2.  Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.

Authors:  Jana Miniarikova; Melvin M Evers; Pavlina Konstantinova
Journal:  Mol Ther       Date:  2018-02-08       Impact factor: 11.454

3.  Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model.

Authors:  Lorelei Stoica; Sophia H Todeasa; Gabriela Toro Cabrera; Johnny S Salameh; Mai K ElMallah; Christian Mueller; Robert H Brown; Miguel Sena-Esteves
Journal:  Ann Neurol       Date:  2016-03-11       Impact factor: 10.422

4.  Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease.

Authors:  Bryan Zeitler; Steven Froelich; Kimberly Marlen; David A Shivak; Qi Yu; Davis Li; Jocelynn R Pearl; Jeffrey C Miller; Lei Zhang; David E Paschon; Sarah J Hinkley; Irina Ankoudinova; Stephen Lam; Dmitry Guschin; Lexi Kopan; Jennifer M Cherone; Hoang-Oanh B Nguyen; Guijuan Qiao; Yasaman Ataei; Matthew C Mendel; Rainier Amora; Richard Surosky; Josee Laganiere; B Joseph Vu; Anand Narayanan; Yalda Sedaghat; Karsten Tillack; Christina Thiede; Annette Gärtner; Seung Kwak; Jonathan Bard; Ladislav Mrzljak; Larry Park; Taneli Heikkinen; Kimmo K Lehtimäki; Marie M Svedberg; Jenny Häggkvist; Lenke Tari; Miklós Tóth; Andrea Varrone; Christer Halldin; Andrea E Kudwa; Sylvie Ramboz; Michelle Day; Jyothisri Kondapalli; D James Surmeier; Fyodor D Urnov; Philip D Gregory; Edward J Rebar; Ignacio Muñoz-Sanjuán; H Steve Zhang
Journal:  Nat Med       Date:  2019-07-01       Impact factor: 53.440

Review 5.  Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets.

Authors:  Marta Daniela Costa; Patrícia Maciel
Journal:  Cell Mol Life Sci       Date:  2022-05-03       Impact factor: 9.261

6.  A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease.

Authors:  Anna Kotowska-Zimmer; Lukasz Przybyl; Marianna Pewinska; Joanna Suszynska-Zajczyk; Dorota Wronka; Maciej Figiel; Marta Olejniczak
Journal:  Mol Ther Nucleic Acids       Date:  2022-05-05       Impact factor: 10.183

Review 7.  Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.

Authors:  Megan S Keiser; Holly B Kordasiewicz; Jodi L McBride
Journal:  Hum Mol Genet       Date:  2015-10-26       Impact factor: 6.150

Review 8.  Role of MicroRNAs, Aptamers in Neuroinflammation and Neurodegenerative Disorders.

Authors:  Islauddin Khan; Kumari Preeti; Valencia Fernandes; Dharmendra Kumar Khatri; Shashi Bala Singh
Journal:  Cell Mol Neurobiol       Date:  2021-05-01       Impact factor: 4.231

Review 9.  Gene, Stem Cell, and Alternative Therapies for SCA 1.

Authors:  Jacob L Wagner; Deirdre M O'Connor; Anthony Donsante; Nicholas M Boulis
Journal:  Front Mol Neurosci       Date:  2016-08-12       Impact factor: 5.639

10.  Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease.

Authors:  Jana Miniarikova; Ilaria Zanella; Angelina Huseinovic; Tom van der Zon; Evelyn Hanemaaijer; Raygene Martier; Annemart Koornneef; Amber L Southwell; Michael R Hayden; Sander J van Deventer; Harald Petry; Pavlina Konstantinova
Journal:  Mol Ther Nucleic Acids       Date:  2016-03-22       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.